Hello again Readers, and dare I say winners!
Well that’s almost a certainty if you follow today’s potential scorcher,
LCAR!
LCAR engages in the research, testing, and development of medications for the control and cure of various diseases in the United States, Europe, and South Korea.
What’s even more interesting than their lead product, Catrix, is their current insanely perfect looking technical setup. We’re talking a real probable triple digit gusher.
We look at the evidence and facts. If you were to take LCAR’s share statistics from Yahoo Finance: shares outstanding verses float and percentage held by insiders verses institutions. Those favorable numbers combined with its current technical setup could equal an eruption of monumental momentum gains. Triple digit almost certainly, possibly even higher.
Biotech has been on a hot streak for the past several years and some analysts predict that this will continue straight into 2016.Brand sales increased at double digit rates for 2015, with torrid pace to continue in 2016 due to positive demographic factors, an improving US economy and a bumper crop of specialty biologic products. Generic sales growth is significantly lower, at 3 per cent. Worldwide sales of all drugs have surpassed the trillion dollar mark; IMS forecasts a 1.3 trillion dollar market by 2018.
BUSINESS SUMMARY
(LCAR - Lescarden Inc.)
http://www.lescarden.com/
Lescarden Inc. or
LCAR engages in the research, testing, and development of medications. The company’s lead product is Catrix Wound Dressing for the management of chronic lesions and burns, as well as for non-healing wounds, such as decubitus ulcers, venous stasis ulcers, and diabetic ulcers. The company doubles as a biopharmaceutical company as well as providing skin care products for medical and skin care.
The company shows successful entries into the Asian markets as proof of all the following news showing several distribution, licensing and new market entry deals:
http://catrix.com/news/index.htm
Founded in 1960 by the late John Prudden MD, MED. Sc.D., a Harvard-trained physician known as the “father of cartilage therapy.” As an Associate Professor of Clinical Surgery at Columbia Presbyterian Medical Center in 1954, Dr. Prudden first observed the extraordinary properties in cartilage while investigating various materials in an effort to reverse the negative effects that corticosteroids had on wound healing. Applying cartilage powder to open wounds, Dr. Prudden enthusiastically noted that the substance accelerated the wound healing and reduced inflammation of the surrounding tissues.
Numerous studies, by the Lescarden research team as well as other leading scientists, have continued to define and expand upon the array of beneficial pharmacological properties of bovine cartilage both topically and systemically. Years of product testing and refinement has led to the creation of Lescarden’s proprietary formula for purifying bovine cartilage producing a sterile white powder that optimizes the healing and anti-inflammatory processes. Today, the company’s exclusive bovine cartilage powder, marketed as Catrix®, is FDA and EU approved for the management of chronic wounds and severe burns.
LCAR offers a the Catrix-based wound and skin care products for plastic surgery, dermatology, and medical spa markets. In addition, the company provides nutritional supplements comprising Bio-Cartilage and Poly-NAG, a patented glucosamine polymer.
Further, it licenses its technologies for commercialization by other companies. Lescarden Inc. was founded in 1960 and is based in New York, New York.
Read more:
http://finance.yahoo.com/q/pr?s=LCAR+Profile
MARKET OUTLOOK
The global skin care products industry revenue is forecast to reach an estimated $102.3 billion in 2018 with good growth over the next five years. Rising living standards and increased spending power are anticipated to drive demand for newer skin care products.
On the biopharmaceutical side it was found that the sector generates global revenues of $163 billion, making up about 20 percent of the pharma market.
In a thorough outlook report by McKinsey & Company they find that biopharmaceuticals is big and growing too rapidly to ignore.
It’s by far the fastest-growing part of the industry: biopharma’s current annual growth rate of more than 8 percent is double that of conventional pharma, and growth is expected to continue at that rate for the foreseeable future.
The efficacy and safety of biopharmaceutical products, combined with their ability to address previously untreatable conditions, allows pharma companies to command high prices for innovative drugs. Strong demand has driven significant profits, despite the high cost of goods sold.
Biopharmaceuticals have set new standards for blockbuster drugs as well. Blockbusters are traditionally defined as drugs that have $1 billion or more in annual sales; the top 15 biopharma products each enjoy annual revenue of more than $2 billion, with some, such as the anti-inflammatory drug Humira, generating sales of more than $10 billion a year. For many players, the biggest challenge has been simply making enough product to sell. It’s no surprise that major pharmaceutical companies around the world are increasingly shifting their R&D and sourcing focus to large-molecule products.
If anything, the emerging long-term picture is even more exciting, with disruptive innovations such as immunotherapies, antibody drug conjugates, and gene and cell therapies all making progress toward commercial launch in the next few years. Biopharma looks poised to transform the industry once more, as increasing understanding of the interaction between drugs and the genetic makeup of patients helps to improve the targeting of therapies. Combined with robust, low-cost genetic profiling, this knowledge will improve treatment outcomes and serve to accelerate and improve the outcomes of clinical trials, helping to reduce the cost of drug development.
Read More Here.
There you have it folks, start your own research now! Remember to always use sound money management and have good trading discipline. And never risk more than you could afford to lose.
Enjoy the day!
